Integrum AB (publ)

Hello, and welcome to today's webcast with Intergrum, where CEO Makko Winsten and CFO Jørgen Svansten will be presenting.

After the presentation, there'll be a Q&A, so if you have any questions, please submit using the form to the right. And with that said, please go ahead with your presentation.

Thank you, Martin. Yes, my name is Martin Hilsten. I joined Integrum early May this year as the new CEO. And next to me is Jørgen Svanström, our CEO. We will hold this presentation for you this morning. Welcome, everyone. So just a quick recap of what Integrum is all about. We are a Swedish company located in Gothenburg. We are commercially active in US and Europe and Australia. 35 people working here in Gothenburg and about 12 people in the US office in Boston area. We are listed on First North, as you probably know, and we founded in 1998. Next. Our vision is freedom of mobility for every person and our mission to transform the lives of people with mobility challenges with cutting edge solutions today and tomorrow. So this technology is actually driven from the first invention of the dental implants and the osseointegration founded in in the 60s here actually here in Gothenburg this company integrum was founded in 1998 and was CE marking the opera system in 1999 and what we're working with today is the opera system and we have the DE marking and the MDR certificates and we also have the PMA for US, which was launched in 2020. So US, our main market, but we are also in Europe and Australia. As you can see, the Scandinavian countries, UK, Benelux, Germany, or the Dutch area, Israel, Slovenia, and Ukraine, as you probably have heard of. So we are working with amputees and changing the lives for those people. And about 3.9 million people living with amputees, limb loss in the US and in Europe. And in US and Europe alone, about 350,000 amputations are performed every year. And in the US, about 120,000 are transfemoral amputees, which is our main patient group in the US. So the OPERA implant system, the OPERA is the abbreviation of Osseoanchored Prosthesis for Rehabilitation of Amputees. And the opera system for Europe for the CE mark under the MDR regulation is transhumeral above elbow. We have thumb and fingers and we have the transfemoral above knee amputees. And for the FDA, FDA PMA approval is the transfemoral, the above knee indication. So the OPERA system is basically a fixture. It's an implant which is placed in, in this case, in femur. And on top of the fixture, we're placing an abutment. And on the abutment, we are placing the OPERA axor device, which is the connector between the OPERA system and the prosthesis, which can be supplied by different suppliers. So our patient centric team approach, we have talking to the market about our go to market strategy with centers of excellence with the patient in the center and we working together with the hospitals, with the surgeons. We are working together with the CPOs, which is the prosthetist who have a daily contact with the amputees. And obviously our R&D team here in Gothenburg at the Tech Room and all the community that holding these entities informed and what kind of products we can offer them. So what we trying to do is improve the quality of life for this patient for this patient group and improved inpatient quality of life elimination of socket related problems which is the main issue for transfemoral amputees enhancing the osteoporosis and embodiment which means actually the connection between the prosthesis and the the body which is linked to Improved mobility and range of motion. Ease in attaching and detaching the prosthesis, which is a major issue and the Axra device makes it very easy for the patient. Improvement and ability to perform activities of daily living. So this quarter, Jørgen will go through the numbers for this quarter, but in general, we have a positive sales performance, especially in the US, and this is something that we focus strongly after the strategic shift earlier this year. Increased use of the OPERA implant system, so we are increasing the numbers of surgeries, the S1 number that we have communicated before. And we also have increased visibility in a growth industry. So we are improving our footprint in the osseointegration prosthesis environment. Next one. So I'm handing over to Jørgen to go through the numbers for our last quarter.